These results revealed that utilization of mTOR inhibitor could be a potential pharmacological approach for temporally extending life span, antigen-presenting and antigen processing of DCs to improve the therapeutic outcome of cancer immunotherapy (160). This evidence concerns the gene MTOR and cancer.